## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12$ 

Name of entity					
Atlas	Atlas Pearls and Perfumes Ltd				
ABN					
32 00	9 220 053				
We (t	We (the entity) give ASX the following information.				
	Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).				
1	*Class of *securities issued or to be issued	Fully paid ordinary shares.			
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	2,000,000 Fully paid ordinary shares.			
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares.			

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes - Fully paid ordinary shares.
5	Issue price or consideration	\$100,000.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of 2,000,000 fully paid ordinary shares on conversion of 100,000 Convertible Notes pursuant to the terms and conditions of the Convertible Notes approved by shareholders at a General Meeting of Shareholders held on 4 December 2012.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	9 September 2014	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	328,616,452	Fully paid ordinary shares (ASX code: ATP)

<sup>+</sup> See chapter 19 for defined terms.

Number and +class of all 9 +securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
1,000,000	Convertible notes.
20,000,000	Unlisted options exercisable at \$0.0858 each on or before 31 December 2016.
8,500,000	Unlisted options exercisable at \$0.095 each on or before 31 December 2016.

trust, distribution policy) on the increased capital (interests)

Dividend policy (in the case of a Dividends are paid as authorised by Directors.

### Part 2 - Bonus issue or pro rata issue

11	required?	N/A
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
	<u> </u>	

18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

<sup>+</sup> See chapter 19 for defined terms.

30		do <sup>+</sup> security holders sell entitlements <i>in full</i> through ker?		
31	<i>part</i> throu	do *security holders sell of their entitlements gh a broker and accept for alance?		
32	of the	do <sup>+</sup> security holders dispose eir entitlements (except by hrough a broker)?		
33	†Desp	oatch date		
	-	uotation of Securities		
34	Type (tick o	of securities one)		
(a)		Securities described in Part		
(b)			nd of the escrowed period, partly paid securities that become fully paid, on restriction ends, securities issued on expiry or conversion of convertible	
Entities that have ticked box 34(a)				
Additional securities forming a new class of securities				
Tick to docume		e you are providing the informat	ion or	
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities	
36		+securities setting out the nu 1 - 1,000 1,001 - 5,000	securities, a distribution schedule of the additional amber of holders in the categories	
		5,001 - 10,000 10,001 - 100,000		
		100 001 and over		

37	A copy of any trust deed for the additional *securities				
Entiti	Entities that have ticked box 34(b)				
38	Number of securities for which †quotation is sought	N/A			
39	Class of *securities for which quotation is sought				
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?				
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment				
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period				
	(if issued upon conversion of another security, clearly identify that other security)				
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Number	+Class		

#### Quotation agreement

<sup>+</sup> See chapter 19 for defined terms.

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Al Hum.	Date: 10 September 2014
Ü	( <del>Director</del> /Company secretary)	,
Print name:	SUSAN HUNTER	

== == == ==

NOII L

## Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	Not applicable.	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	Not applicable.	
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Not applicable.	
"A"	Not applicable.	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
<b>Multiply</b> "A" by 0.15	Not applicable.		
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule		
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Not applicable.		
• Under an exception in rule 7.2			
Under rule 7.1A			
• With security holder approval under rule 7.1 or rule 7.4			
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"	Not applicable.		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	Not applicable.		
Note: number must be same as shown in Step 2			
Subtract "C"	Not applicable.		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	Not applicable. [Note: this is the remaining placement capacity under rule 7.1]		

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	Not applicable.	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D" Not applicable.		
	Note: this value cannot be changed	
Multiply "A" by 0.10	Not applicable.	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Not applicable.	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	Not applicable	
"E"	Not applicable.	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	Not applicable.
Note: number must be same as shown in Step 2	
Subtract "E"	Not applicable.
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	Not applicable.
	Note: this is the remaining placement capacity under rule 7.1A